Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: Outcome and clinical implications

British Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 992-997

  Viviani, S ^a   Camerini, E ^a   Bonfante, V ^a   Santoro, A ^a   Balzarotti, M ^a   Fornier, M ^a   Devizzi, L ^a   Verderio, P ^a   Valagussa, P ^a   Bonadonna, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hodgkin's disease; Prognostic factor; Soluble interleukin 2 receptor

Indexed keywords

INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 6844257522     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.163     Document Type: Article

References (40)

1. Banks RE, Patel PM and Selly PJ (1995) Interleukin-12: a new clinical player in cylokine therapy. Br J Cancer 71: 655-659
2. Blay JY, Farcet JP, Lavaud A, Radoux D and Chonaih S (1994) Serum concentrations of cytukines in patients with Hodgkin's disease. Eur J Cancer 30A: 321-324
3. Chilosi M, Semenzato G, Vinante F, Menestrina F, Piazzola E, Focchiatti V, Sabbioni R, Zanotti R and Pizzolo G (1989) Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotic features. Am J Clin Pathol 92: 186-191
4. Clerici M, Ferrario H, Trahattoni D, Viviani S, Bonfante V, Venzon DJ, Clerici E, Shearer GM and Villa ML (1994) Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur J Cancer 30A: 1464-1470
5. Cox DR (1972) Regression models and life-tables. J R Stat Soc (B) 34: 187-220
6. Durrleman S and Simon R (1989) Flexible regression models with cubic splines. Stat Med 8: 551-561
7. Enblad G, Sundström C, Gronowitz S and Glimelius B (1995) Serum levels of interleukin-2 receptor (CD25) in patients with Hodgkin's disease, with special reference to age and prognosis. Ann Oncol 6: 65-70
8. Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits R, Diehl V and Pfreundschuh M (1991) Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Ann Oncol 2 (suppl. 2): 43-47
9. Gause A, Jung W, Schmits R, Tschiersch A, Scholz R, Pohl C, Hasenclever D, Diehl V and Pfreundschuh M (1992a) Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol 3 (suppl. 4): S49-S52
10. Gause A, Keymis S, Scholz R, Schobert J, Jung W, Diehl V, Pohl C and Pfreundschuh M (1992b) Increased levels of circulating cytokines in patients with untreated Hodgkin's disease. Lymphokine, Cytokine Res 11: 109-113
11. Gooding R, Riches P, Dadian G, Moore J and Gore M (1995) Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Canter 72: 452-455
12. Gorschluter M, Bohlen H, Hasenclever D, Diehl V and Tesch H (1995) Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 6: 477-482
13. Grimfors G, Andersson B, Tullgren O, Giscombe R, Holm G, Johansson B and Björkholm M (1991) Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease. Br J Haematol 80: 166-171
14. Howard M and O'Garra A (1992) Biological properties of Interleukin-10. Immunol Today 13: 198-200
15. Hsu PL and Hsu SM (1990) Production of tumor necrosis factor-alpha and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2. Am J Pathol 135: 735-745
16. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
17. Kloster BE, John PA, Miller LE, Rubin LA, Nelson DL, Blair DC and Tomar RH (1987) Soluble IL-2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol 45: 440-446
18. Kretschmer C, Jones DB, Morrison K, Schluter C, Feist W, Ulmei AJ, Arnoldi J, Matthes J, Diamantstein T and Flad HD (1990) Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease. Am J Pathol 137: 341-351
19. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J and Talpaz M (1993) Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 53: 2118-2122
20. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA and Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Costwolds Meeting. J Clin Oncol 7: 1630-1636
21. Matsuda T and Hirano T (1990) Interleukin-6 (IL-6). Biotherapy 2: 363-373
22. Motoi T, Uchiyama T, Hori T, Itoh K, Uchino H and Ueda R (1989) Elevated serum soluble interleukin-2 receptor (TAC antigen) levels in chronic inyelogenous leukemia patients with blastic crisis. Blood 74: 1052-1057
23. Pfreundschuh M, Pohl C, Berenbeck C, Schroeder J, Jung W, Schmits R, Tschiersch A, Diehl V and Gause A (1990) Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma. adult T-cell leukemia and infection mononucleosis. Int J Cancer 45: 869-874
24. Pizzolo G, Chilosi M, Vinante F, Dazzi F, Lestani M, Perona G, Benedetti F, Todeschini G, Vincenzi C, Trentin L and Semenzato G (1987) Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer 55: 427-428
25. Proctor S J, Taylor P, Mackie M J, Donnan P, Boys R, Lennard A and Prescott RJ (1992) A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Leukemia Lymphoma 7 (suppl.): 17-20
26. Pui CH, Ip SH, Iflah S, Behm FG, Grose BH, Dodge RK, Crist WM, Furman WL, Murphy SB and Rivera GK (1988) Serum interleukin-2 receptor levels in childhood acute lymphoblastic leukemia. Blood 71: 1135-1137
27. Pui CH, Ip SH, Thompson E, Wiliams J, Brown M, Dodge RK, de Hoyos RA, Berard CW and Crist WM (1989a) High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's disease. Leukemia 3: 481-484
28. Pui CH, Ip SH, Thompson E, Dodge RK, Brown M, Wiliams J, Carrabis S, Kung P, Berard CW and Crist WM (1989b) Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood 73: 209-213
29. Romagnani S, Rossi Ferrini P L and Ricci M (1985) The immune derangement in Hodgkin's disease. Semin Hematol 22: 41-55
30. Rovelli F, Lissoni P, Crispino S, Barni S, Fumagalli G, Paolorossi F and Tancini G (1988) Increased levels of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori 74: 633-637
31. Rubin LA and Nelson DL (1990) The soluble Interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 113: 619-627
32. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boulin B, Yarchoan R and Nelson DL (1985) Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3177
33. Rubin LA, Joy G and Nelson D (1986) The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 137: 3841-3844
34. Santoro A and Valagussa P (1992) Advances in the treatment of Hodgkin's disease. Current Opin Oncol 4: 821-828
35. Semenzato G, Foa R, Agostini C, Zambello R, Trentin L, Vinante F, Benedetti F, Chilosi M and Pizzolo G (1987) High serum levels of soluble interleukin-2 receptor (sIL-2R) in patients with B chronic lymphocytic leukemia (C-cell). Blood 70: 396-399
36. Specht L, Nordentoft AM, Cold S, Clausen NT and Nissen NI (1988) Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relation to other prognostic factors and implications for choice of treatment. Cancer 61: 1719-1727
37. Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL and Maluish AE (1988) Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 71: 1304-1309
38. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J and Clarkson BD (1990) Prognostic factors among 185 adults with newly-diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J Ctin Oncol 8: 1173-1186
39. Trümper L, Jung W, Dahl G, Diehl V, Gause A and Pfreundschuh M (1994) Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 5 (suppl. 1): S93-S96
40. Wanebo HJ, Pace R, Hargett S, Katz D and Sando J (1986) Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer 57: 656-662